Comparison of Adjuvant Systemic Chemotherapy With or Without Hepatic Arterial Infusional Chemotherapy After Hepatic Resection for Metastatic Colorectal Cancer

Background:The potential benefit of adjuvant hepatic arterial infusional floxuridine (HAI-FUDR) in addition to modern systemic chemotherapy using oxaliplatin or irinotecan remains unknown for patients with resected liver-confined colorectal metastases (CRLM). The principle aim of this study was to compare outcomes in patients receiving modern systemic chemotherapy with or without HAI-FUDR. Methods:Between 2000 and 2005, 125 patients underwent resection of CRLM followed by adjuvant HAI-FUDR plus dexamethasone (Dex) and concurrent systemic chemotherapy including oxaliplatin or irinotecan. These patients were compared retrospectively to 125 consecutive patients who received modern systemic chemotherapy alone after liver resection. Results:The median follow-up for all patients was 43 months. There were no differences in clinical risk score, disease-free interval, size of largest CRLM, number of CRLM, or prehepatectomy CEA level between the 2 groups. Adjuvant HAI-FUDR was associated with an improved overall and liver recurrence-free survival (liver RFS) and disease-specific survival (DSS). For the adjuvant HAI-FUDR group, the 5-year liver RFS, overall RFS, and DSS were 75%, 48%, and 79%, respectively, compared to 55%, 25%, and 55% for the systemic alone group (P < 0.01). On multivariate analysis, adjuvant treatment including HAI-FUDR was independently associated with improved liver RFS (HR = 0.34), overall RFS (HR = 0.65), and DSS (HR = 0.39), P < 0.01. Conclusions:Adjuvant HAI-FUDR combined with modern systemic chemotherapy is independently associated with improved survival compared to adjuvant systemic chemotherapy alone. A randomized clinical trial between these 2 regimens is justified.

[1]  M. D'Angelica,et al.  Randomized phase II trial of adjuvant hepatic arterial infusion and systemic chemotherapy with or without bevacizumab in patients with resected hepatic metastases from colorectal cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  E. Abdalla Resection of Colorectal Liver Metastases , 2011, Journal of Gastrointestinal Surgery.

[3]  M. Gönen,et al.  Survival after hepatic resection for metastatic colorectal cancer: trends in outcomes for 1,600 patients during two decades at a single institution. , 2010, Journal of the American College of Surgeons.

[4]  M. D'Angelica,et al.  Phase I trial of adjuvant hepatic arterial infusion (HAI) with floxuridine (FUDR) and dexamethasone plus systemic oxaliplatin, 5-fluorouracil and leucovorin in patients with resected liver metastases from colorectal cancer. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[5]  M. Gonen,et al.  Effect of Postoperative Morbidity on Long-term Survival After Hepatic Resection for Metastatic Colorectal Cancer , 2008, Annals of surgery.

[6]  Thomas Gruenberger,et al.  Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial , 2008, The Lancet.

[7]  S. Mocellin,et al.  Meta-analysis of hepatic arterial infusion for unresectable liver metastases from colorectal cancer: the end of an era? , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  Yuman Fong,et al.  Actual 10-year survival after resection of colorectal liver metastases defines cure. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  M. Gonen,et al.  Lack of Evidence for Increased Operative Morbidity After Hepatectomy with Perioperative Use of Bevacizumab: A Matched Case-Control Study , 2007, Annals of Surgical Oncology.

[10]  J. Berlin,et al.  Chemotherapy and Regional Therapy of Hepatic Colorectal Metastases: Expert Consensus Statement , 2006, Annals of Surgical Oncology.

[11]  Catherine Julié,et al.  Complete response of colorectal liver metastases after chemotherapy: does it mean cure? , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  N. Kemeny,et al.  Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer: a randomized trial of efficacy, quality of life, and molecular markers (CALGB 9481). , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  S. Curley,et al.  OncoSurge: a strategy for improving resectability with curative intent in metastatic colorectal cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  L. Schwartz,et al.  Phase I trial of systemic oxaliplatin combination chemotherapy with hepatic arterial infusion in patients with unresectable liver metastases from colorectal cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  L. Ben-Porat,et al.  Technical complications and durability of hepatic artery infusion pumps for unresectable colorectal liver metastases: an institutional experience of 544 consecutive cases. , 2005, Journal of the American College of Surgeons.

[16]  M. Gonen,et al.  Hepatic arterial infusion after liver resection. , 2005, The New England journal of medicine.

[17]  Bernard Paule,et al.  Rescue Surgery for Unresectable Colorectal Liver Metastases Downstaged by Chemotherapy: A Model to Predict Long-term Survival , 2004, Annals of surgery.

[18]  M. Gonen,et al.  Phase I/II study of hepatic arterial therapy with floxuridine and dexamethasone in combination with intravenous irinotecan as adjuvant treatment after resection of hepatic metastases from colorectal cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  M. Gonen,et al.  The management of variant arterial anatomy during hepatic arterial infusion pump placement , 2002, Annals of Surgical Oncology.

[20]  F. Lévi,et al.  Five-Year Survival Following Hepatic Resection After Neoadjuvant Therapy for Nonresectable Colorectal [Liver] Metastases , 2001, Annals of Surgical Oncology.

[21]  H. Bismuth,et al.  Two-Stage Hepatectomy: A Planned Strategy to Treat Irresectable Liver Tumors , 2000, Annals of surgery.

[22]  L H Blumgart,et al.  Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. , 1999, Annals of surgery.

[23]  T. Starzl,et al.  Hepatic resection for metastatic colorectal adenocarcinoma: a proposal of a prognostic scoring system. , 1999, Journal of the American College of Surgeons.

[24]  F. Lévi,et al.  Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. , 1996, Annals of surgery.

[25]  B. Nordlinger,et al.  Surgical resection of colorectal carcinoma metastases to the liver: A prognostic scoring system to improve case selection, based on 1568 patients , 1996, Cancer.

[26]  L. R. Hill,et al.  A prospective, randomized evaluation of the treatment of colorectal cancer metastatic to the liver. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  W. Jarnagin,et al.  Importance of response to neoadjuvant chemotherapy in patients undergoing resection of synchronous colorectal liver metastases , 2003, Journal of Gastrointestinal Surgery.

[28]  F. Lévi,et al.  Five-year survival following hepatic resection after neoadjuvant therapy for nonresectable colorectal. , 2001, Annals of surgical oncology.

[29]  M. Lorenz,et al.  Randomized, multicenter trial of fluorouracil plus leucovorin administered either via hepatic arterial or intravenous infusion versus fluorodeoxyuridine administered via hepatic arterial infusion in patients with nonresectable liver metastases from colorectal carcinoma. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.